ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1340

Nutrition-Related Behaviors and Beliefs – A Survey of Rheumatic Disease Patients

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1187

Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1566

Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1420

Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1165

Pathogenicity of IL-17 Producing Cells in HLA-B27 Transgenic Rat Model of Spondyloarthritis

Spondyloarthritis Including PsA – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1367

Patient and Physician Reported Outcomes of Juvenile Systemic Sclerosis Patients Significantly Improve over 12 Months Observation Period in the Juvenile Systemic Scleroderma Inception Cohort

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1509

Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1333

Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1356

Patient-perceived Disease Burden and Self-reported Medication Adherence in Systemic Autoimmune Diseases: A Monocentric Observational Study

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1344

Patient-reported Outcomes in Lupus Low Disease Activity State: Impact of Fatigue

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1464

Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1444

Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1280

Patients with Systemic Lupus Erythematosus Perceive the Quality of Care They Receive to Be Suboptimal

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1338

Patients’ Perspectives and Experiences of Medication Use in Osteoporosis – a Qualitative Systematic Review and Thematic Synthesis

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1452

Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].